277 related articles for article (PubMed ID: 32018275)
1. Febrile Neutropenia in a Patient with Non-Small Cell Lung Cancer Treated with the Immune-Checkpoint Inhibitor Nivolumab.
Hisamatsu Y; Morinaga R; Watanabe E; Ohtani S; Shirao K
Am J Case Rep; 2020 Feb; 21():e920809. PubMed ID: 32018275
[TBL] [Abstract][Full Text] [Related]
2. [Effectiveness of a Low-dose Corticosteroid in a Patient with Polymyalgia Rheumatica Associated with Nivolumab Treatment].
Imai Y; Tanaka M; Fujii R; Uchitani K; Okazaki K
Yakugaku Zasshi; 2019; 139(3):491-495. PubMed ID: 30828027
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab-related severe thrombocytopenia in a patient with relapsed lung adenocarcinoma: a case report and review of the literature.
Hasegawa T; Ozaki Y; Inoue T; Watanabe Y; Fukuhara M; Yamaura T; Muto S; Okabe N; Higuchi M; Shio Y; Suzuki H
J Med Case Rep; 2019 Oct; 13(1):316. PubMed ID: 31647029
[TBL] [Abstract][Full Text] [Related]
4. Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature.
Ohara N; Kobayashi M; Ohashi K; Ito R; Ikeda Y; Kawaguchi G; Yoneoka Y; Hasegawa G; Takada T
J Med Case Rep; 2019 Mar; 13(1):88. PubMed ID: 30909965
[TBL] [Abstract][Full Text] [Related]
5. Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor.
Alessandrino F; Sahu S; Nishino M; Adeni AE; Tirumani SH; Shinagare AB; Awad MM
Abdom Radiol (NY); 2019 May; 44(5):1917-1927. PubMed ID: 30790009
[TBL] [Abstract][Full Text] [Related]
6. Bicytopenia in Primary Lung Melanoma Treated with Nivolumab.
Takahashi A; Kubo A; Mizuno S; Kasai K; Asai N; Yonezawa T; Kosaka K; Nishimura M; Tanaka H; Yokoe N; Tsuzuki T; Takami A; Yamaguchi E
Intern Med; 2019 Mar; 58(6):827-831. PubMed ID: 30449777
[TBL] [Abstract][Full Text] [Related]
7. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition.
Naqash AR; Appah E; Yang LV; Muzaffar M; Marie MA; Mccallen JD; Macherla S; Liles D; Walker PR
J Immunother Cancer; 2019 Jul; 7(1):169. PubMed ID: 31277704
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report.
Koda R; Watanabe H; Tsuchida M; Iino N; Suzuki K; Hasegawa G; Imai N; Narita I
BMC Nephrol; 2018 Feb; 19(1):48. PubMed ID: 29486725
[TBL] [Abstract][Full Text] [Related]
9. Immune-related intestinal pseudo-obstruction associated with nivolumab treatment in a lung cancer patient.
Fragulidis G; Pantiora E; Michalaki V; Kontis E; Primetis E; Vezakis A; Polydorou A
J Oncol Pharm Pract; 2019 Mar; 25(2):487-491. PubMed ID: 29067858
[TBL] [Abstract][Full Text] [Related]
10. Recurrent Episodes of Nivolumab-Induced Pneumonitis after Nivolumab Discontinuation and the Time Course of Carcinoembryonic Antigen Levels: A Case of a 58-Year-Old Woman with Non-Small Cell Lung Cancer.
de Jong C; Peters BJM; Schramel FMNH
Chemotherapy; 2018; 63(5):272-277. PubMed ID: 30572331
[TBL] [Abstract][Full Text] [Related]
11. High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review.
Koyama N; Iwase O; Nakashima E; Kishida K; Kondo T; Watanabe Y; Takahashi H; Umebayashi Y; Ogawa Y; Miura H
BMC Pulm Med; 2018 Jan; 18(1):23. PubMed ID: 29378571
[TBL] [Abstract][Full Text] [Related]
12. Safe and effective use of nivolumab for treating lung adenocarcinoma associated with sporadic lymphangioleiomyomatosis: a rare case report.
Pluvy J; Brosseau S; Stelianides S; Danel C; Nguenang M; Khalil A; Crestani B; Zalcman G; Gounant V
BMC Pulm Med; 2019 Jan; 19(1):12. PubMed ID: 30634951
[TBL] [Abstract][Full Text] [Related]
13. Anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis induced by nivolumab for lung adenocarcinoma: A case report.
Osaki M; Tachikawa R; Ohira J; Hara S; Tomii K
Invest New Drugs; 2021 Feb; 39(1):251-255. PubMed ID: 32651759
[TBL] [Abstract][Full Text] [Related]
14. Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program.
Baldini E; Lunghi A; Cortesi E; Turci D; Signorelli D; Stati V; Melotti B; Ricciuti B; Frassoldati A; Romano G; Ceresoli GL; Illiano A; Verderame F; Fasola G; Ricevuto E; Marchetti P; Pinto C; Cartenì G; Scotti V; Tibaldi C; Fioretto L; Giannarelli D
Lung Cancer; 2020 Feb; 140():59-64. PubMed ID: 31881412
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab.
Oyanagi J; Koh Y; Sato K; Mori K; Teraoka S; Akamatsu H; Kanai K; Hayata A; Tokudome N; Akamatsu K; Nakanishi M; Ueda H; Yamamoto N
Lung Cancer; 2019 Jun; 132():107-113. PubMed ID: 31097082
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab-induced adrenalitis.
Iqbal I; Khan MAA; Ullah W; Nabwani D
BMJ Case Rep; 2019 Dec; 12(11):. PubMed ID: 31791986
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab-Induced Polymyalgia Rheumatica in a Patient with Lung Adenocarcinoma.
Kita T; Araya T; Sakai T; Uchida Y; Matsuoka H; Kasahara K
Am J Med Sci; 2021 Sep; 362(3):321-323. PubMed ID: 33905737
[TBL] [Abstract][Full Text] [Related]
18. Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy.
Fujita K; Kim YH; Kanai O; Yoshida H; Mio T; Hirai T
Respir Med; 2019 Jan; 146():66-70. PubMed ID: 30665520
[TBL] [Abstract][Full Text] [Related]
19. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.
Wrangle JM; Velcheti V; Patel MR; Garrett-Mayer E; Hill EG; Ravenel JG; Miller JS; Farhad M; Anderton K; Lindsey K; Taffaro-Neskey M; Sherman C; Suriano S; Swiderska-Syn M; Sion A; Harris J; Edwards AR; Rytlewski JA; Sanders CM; Yusko EC; Robinson MD; Krieg C; Redmond WL; Egan JO; Rhode PR; Jeng EK; Rock AD; Wong HC; Rubinstein MP
Lancet Oncol; 2018 May; 19(5):694-704. PubMed ID: 29628312
[TBL] [Abstract][Full Text] [Related]
20. Unusual skin toxicity associated with sustained disease response induced by nivolumab in a patient with non-small cell lung cancer.
Galli G; Proto C; Cossa M; Valeri B; Sdao S; Signorelli D; Imbimbo M; de Braud F; Garassino MC; Lo Russo G
Tumori; 2019 Dec; 105(6):NP57-NP62. PubMed ID: 31456503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
